Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

(2013) J. D. Wolchok et al.   ANNALS OF ONCOLOGY

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

(2013) Bastian Schilling et al.   INTERNATIONAL JOURNAL OF CANCER

Which drug, and when, for patients with BRAF-mutant melanoma?

(2013) Sekwon Jang et al.   LANCET ONCOLOGY

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

(2012) Yuko Shirota et al.   ANNALS OF THE RHEUMATIC DISEASES

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells

(2012) Rahul Purwar et al.   NATURE MEDICINE

Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment

(2012) Margaret K. Callahan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Blocking MAPK Signaling Downregulates CCL21 in Lymphatic Endothelial Cells and Impairs Contact Hypersensitivity Responses

(2011) Tomomitsu Miyagaki et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Immunologic functions as prognostic indicators in melanoma

(2011) Marna G. Bouwhuis et al.   Molecular Oncology

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations

(2010) B. Comin-Anduix et al.   CLINICAL CANCER RESEARCH

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Heterogeneity and plasticity of T helper cells

(2009) Jinfang Zhu et al.   CELL RESEARCH

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY